Weaving a blanket to protect the entire airway: The goal of comprehensive therapy

Annals of Allergy, Asthma and Immunology

Volumn 93, Issue 5, 2004, Pages 407-408

  Weber, Richard W ^a  

^a NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; ANTIHISTAMINIC AGENT; BECLOMETASONE; FEXOFENADINE; FLUTICASONE; LEUKOTRIENE; MONTELUKAST; SALMETEROL; STEROID;

AIRWAY; ALLERGENICITY; ALLERGIC RHINITIS; ASTHMA; CAT; DANDER; DISEASE ASSOCIATION; DISEASE EXACERBATION; DRUG EFFICACY; DRUG POTENCY; EDITORIAL; EXPOSURE; HUMAN; LOWER RESPIRATORY TRACT; MONOTHERAPY; PRIORITY JOURNAL; PROVOCATION TEST; SIDE EFFECT; UPPER RESPIRATORY TRACT;

EID: 8644235851     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)61405-6     Document Type: Editorial

References (12)

1. Bousquet J, Van Cauwenberge P, Khaltaev N; Aria Workshop Group; World Health Organization. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol. 2001;108 (Suppl): S147-S334.
2. Corren J, Manning BE, Thompson SF, Hennessy S, Strom BL. Rhinitis therapy and the prevention of hospital care for asthma: a case-control study. J Allergy Clin Immunol. 2004;113: 415-419.
3. Perry TT, Corren J, Philip G, et al. Protective effect of montelukast on lower and upper respiratory tract responses to short-term cat allergen exposure. Ann Allergy Asthma Immunol. 2004; 93:431-438.
4. van Adelsberg J, Philip G, Pedinoff AJ, et al; Montelukast Fall Rhinitis Study Group. Montelukast improves symptoms of seasonal allergic rhinitis over a 4-week treatment period. Allergy. 2003;58:1268-1276.
5. Chervinsky P, Philip G, Malice MP, et al. Montelukast for treating fall allergic rhinitis: effect of pollen exposure in 3 studies. Ann Allergy Asthma Immunol. 2004;92:367-373.
6. Baumgartner RA, Martinez G, Edelman JM, et al. Distribution of therapeutic response in asthma control between oral montelukast and inhaled beclomethasone. Eur Respir J. 2003;21: 123-128.
7. Nathan RA. Pharmacotherapy for allergic rhinitis: a critical review of leukotriene receptor antagonists compared to other treatments. Ann Allergy Asthma Immunol. 2003;90:182-190.
8. Grayson MH, Korenblat PE. The emerging role of leukotriene modifiers in allergic rhinitis. Am J Respir Med. 2003;2: 441-450.
9. Pullerits T, Praks L, Ristioja V, Lötvall J. Comparison of a nasal glucocorticoid, antileukotriene, and a combination of antileukotriene and antihistamine in the treatment of seasonal allergic rhinitis. J Allergy Clin Immunol. 2002;109:949-955.
10. Laviolette M, Malmstrom K, Lu S, et al. Montelukast added to inhaled beclomethasone in treatment of asthma. Am J Respir Crit Care Med. 1999;160:1862-1868.
11. Lee DKC, Jackson CM, Haggart K, Lipworth BJ. Repeated dosing effects of mediator antagonists in inhaled corticosteroid-treated atopic asthmatic patients. Chest. 2004;125:1372-1377.
12. Bjermer L, Bisgaard H, Bousquet J, et al. Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: one year, double blind, randomised, comparative trial. BMJ. 2003;327:891.